

A Rare Case of Pneumonia and Haemoptysis Caused by *Citrobacter Freundii* in a Young Immunocompetent Male

Sushil Upadhyay

Senior Consultant Chest Physician, Holy Family Hospital, Okhla Road, Delhi

Abstract

Citrobacter infections are often nosocomially acquired, seen in patients with significant underlying diseases and isolates are commonly drug-resistant. A rare clinical syndrome of haemoptysis with underlying pneumonia caused by *Citrobacter freundii* in a immunocompetent young male is presented.

Key Words: *Citrobacter*, *Pneumonia*, *Immunocompetent*


Introduction

Citrobacter genus belongs to family of Enterobacteriaceae and comprises of 11 different species of straight, facultative anaerobic, motile, Gram-negative bacilli which are oxidase negative and utilize citrate as sole carbon source¹. They are commonly found in water, soil, food, and the intestinal tracts of animals and humans². *Citrobacter* infections typically occur in hospital settings in patients with multiple comorbidities and seldom cause disease in the general population³. Urinary tract is the most common site of infection and pneumonia is reported as least common form of infection by *Citrobacter* species⁴. Community acquired human infections by *Citrobacter* species are extremely rare and occur at the extremes of age or in the immunocompromised⁵. It has been rarely cultured in the bronchoscopy specimen done for the evaluation of hemoptysis⁶. The case is being reported because of extremely rare combination of immunocompetent host from community setting presenting with haemoptysis, diagnosed as right upper lobe pneumonia on imaging, further confirmed by bronchoscopy and finally yielding *Citrobacter freundii* on culture of bronchial washings.

Case Report

Forty four year old male presented in emergency department (ED) with hemoptysis. He complained of one episode of fever 5 days prior followed by expectoration of blood from mouth. Quantity of blood varied between 1 tea-spoon full to 1 table spoon per event which occurred 2-3 times in a day. He had no past medical or surgical

history. He was admitted under general physician. Investigations revealed normal hemogram, renal and liver biochemistries, coagulation parameters. Chest xray (Fig1) showed right upper zone hazy airspace opacity. CT thorax (Fig2) confirmed small patch of consolidation in posterior segment of right upper lobe. He received amoxiclav and azithromycin with haemostatics and pantoprazole. He was referred to respiratory specialist for bronchoscopy. Bronchoscopy (Fig3) showed scanty bleeding from right upper lobe posterior segment without any sign of inflammation. Bronchial washings were sent for detailed investigations. Patient was discharged the very next day on oral amoxycyclav as he was asymptomatic. However he presented again with haemoptysis 2 days after leaving the hospital. Chest xray revealed same RUL opacity. Respiratory review was solicited. Bronchial washing which were sent on previous admission were now available. ZN stain and Gene Xpert were negative for *Mycobacterium tuberculosis*. Cytology was negative for malignant cells. Bacterial culture had grown *Citrobacter freundii* which was resistant to betalactam/lactamase, cephalosporins, aminoglycosides and even carbapenems. It was sensitive only to quinolones, tetracycline, colistin, tigicycline and cotrimoxazole (Fig5). Antibiotics were revised and levofloxacin was given. He was discharged on oral tab of 750mg of Levofloxacin once a day. Patient was followed up in out patient department after 5 days. He was asymptomatic and repeat chest xray (Fig4) showed resolved RUL opacity.



Fig(1&2) Chest Xray and CT scan:RUL faint consolidation




Fig 3.Bronchoscopy: Blood in RUL

Fig 4: Resolved RUL consolidation

Discussion

Citrobacter species are straight, facultative anaerobic, Gram-negative bacilli and are typically motile by means of peritrichous flagellae.. This genus was proposed in 1932 by Werkman and Gillen.. In year 1993, Brenner et al. classified *Citrobacter* into 11 genomic species by DNA hybridization. The leading three species causing human infections are *C. freundii*, *C. koseri*, and *C. Braakii*⁷. *Citrobacter* species are commonly found in water, soil, food, and the intestinal tracts of animals and humans². Two groups of patients are at

risk of acquiring *Citrobacter* infections. The first one is neonates, who may develop sepsis and meningitis and brain abscess (usually less than 2 months of age). The second group is debilitated, aged (≥ 65 years) or immunocompromised patients⁵. The infection may occur as sporadic cases or nosocomial outbreaks. Among the various sites of infection, the urinary tract is the most common, followed by the abdomen, skin/soft tissues (including surgical site infection), and pneumonia. A large surveillance study demonstrated that 0.8% of Gram-negative infection was caused by *Citrobacter* spp.³. In

the hospital settings, *Citrobacter* spp. might account for 3-6% of all *Enterobacteriaceae* causing nosocomial infection.

Mohanty et al from a tertiary care hospital in northern India, isolated *Citrobacter* from routine diagnostic testings from 205 patients from Jan till Dec 2004. They observed that infection was nosocomially acquired in 94.6% patients. One hundred eighty one (88.3%) patients had significant underlying illnesses. Culture yielded *Citrobacter koseri* in 185 (90.2%) and *Citrobacter freundii* in 20 (9.8%) patients. The distribution of isolates was as follows: urine (46.2%), respiratory tract (16.3%), blood (15.8%), pus (12.1%) and sterile body fluids (9.3%). Drug resistance was observed to be more in *C. koseri* as compared to *C. Freundii*¹¹

Ashwin Songara et al from India studied role of bronchoscopy in evaluation of patients with hemoptysis. They found *Citrobacter freundii* to grow in bronchial washings in 2.85% of patients⁶.

In a study of community acquired pneumonia in elderly (>65yrs) Anupam Pillai et al reported *Citrobacter freundii* as causative agent in 2 cases out of 65 study patients⁸

Miguel Angel Ariza-Prota et al in year 2015 reported pneumonia and empyema in a 72 year old Spanish male and claimed to be first reported case of community acquired pneumonia in an immunocompetent male caused by *Citrobacter koseri*⁹.

Kelly Pennington et al from Mayo clinic Rochester in year 2016 reported pneumonia attributable to *Citrobacter koseri* in 60 year old man who on further investigation was found to have adenocarcinoma of lung¹⁰.

To the authors knowledge, this is the first reported case in the literature where a young immunocompetent male presents with community acquired pneumonia and haemoptysis caused by *Citrobacter freundii*.

Patients with *Citrobacter* infection can be identified and confirmed only by culture. Different species can be differentiated by biochemical tests². The treatment of *Citrobacter* infections follows the principles for treatment of other *Enterobacteriaceae* infections. Aminoglycosides, fluoroquinolones, carbapenems, and

the fourth-generation cepheems, such as cefepime and ceftazidime, are the preferred therapeutic agents for *C. freundii* infections. Once a specific strain is isolated from a patient, therapeutic agents should be selected according to the *in vitro* susceptibility results of that strain. The site of infection also influences choice of agents¹².

Conclusion

Citrobacter freundii causing community acquired pneumonia presenting as hemoptysis in an immunocompetent host is a rare infection. Culture and sensitivity of the sample from involved organ is the key to definitive diagnosis and successful treatment.

Ethical Clearance: NA

Conflict of Interest: Nil

Source of Funding: Self

References

1. Janda J. M., Abbott S. L., Cheung W. K. W., Hanson D. F. Biochemical identification of citrobacteria in the clinical laboratory. *Journal of Clinical Microbiology*. 1994;32(8):1850-1854
2. Arens S., Verbist L. Differentiation and susceptibility of *Citrobacter* isolates from patients in a university hospital. *Clinical Microbiology and Infection*. 1997;3(1):53-57
3. Schwartz D. A. *Citrobacter* infections. In: Connor D. H., Chandler F. W., Schwartz D. A., Manz H. J., Lack E. E., editors. *Pathology of Infectious Diseases*. Stanford, Connecticut: Appleton and Lange. 1997. pp. 513-516
4. Samonis G, Karageorgopoulos DE, Kofteridis DP, Matthaïou DK, Sidiropoulou V, Maraki S, Falagas ME. *Citrobacter* infections in a general hospital: characteristics and outcomes. *Eur J Clin Microbiol Infect Dis* 2009;28:61-68
5. Lipsky BA, Hook EW III, Smith AA, Plorde JJ. *Citrobacter* infections in humans: experience at the Seattle Veterans Administration Medical Center and a review of the literature. *Rev Infect Dis* 1980;2:746-760
6. Ashwin Songara, Rohit Mukherjee, Swapnil Shikha, Awadesh P. S. Solanki, Tanay Joshi, Deepika Patel. Role of fiberoptic bronchoscopy in

- evaluation of hemoptysis. *Int J Res Med Sci.* 2016 Jul;4(7):2576-2582
7. Brenner DJ, Grimont PAD, Steigerwalt AG, Fanning GR, Ageron E, Riddle CF. Classification of Citrobacteria by DNA hybridization. *Int J Syst Bacteriol* 1993; 43: 645– 58
 8. Anupa Pillai, Shwet Sabnis, Tushar Kanti Biswas. A study of Community Acquired Pneumonia in the Elderly. *IAIM*, 2019; 6(12): 1-9.
 - 9 Miguel Angel Ariza-Prota, Ana Pando-Sandoval, Marta García-Clemente, Ramón Fernández, and Pere Casan. Community-Acquired Pneumonia and Empyema Caused by *Citrobacter koseri* in an Immunocompetent Patient. Case Reports in Pulmonology Vol 2015.pp:1-6
 10. Kelly Penington, Martin Van Zyl, Patricio Escalante. Citrobacter koseri pneumonia as initial presentation of underlying pulmonary adenocarcinoma. *Clin Med Insights Case Rep* 2016;9:87-89
 11. Mohanty S., Singhal R., Sood S., Dhawan B., Kapil A., Das B. K. *Citrobacter* infections in a tertiary care hospital in Northern India. *Journal of Infection.* 2007;54(1):58–64.
 12. Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC. Bacteremia due to Citrobacter species: significance of primary intraabdominal infection. *Clin Infect Dis* 1996;23:543-549.